Neparvis (Valsartan, Sacubitril)

Sacubitril/valsartan, the active ingredient in Neparvis, is a Angiotensin receptor blocker (ARB) and neprilysin inhibitor combination presented as a tablet for oral use. It treats heart failure with reduced ejection fraction and hypertension in adult patients.

GNH USA supplies Neparvis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neparvis (sacubitril/valsartan) is indicated for cardiovascular conditions that benefit from combined angiotensin receptor blockade and neprilysin inhibition.

- Heart failure with reduced ejection fraction: improves survival and reduces hospital admissions. - Hypertension: lowers systolic and diastolic blood pressure when monotherapy or combination therapy is required.

Neparvis may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Hypotension: symptomatic low blood pressure, often orthostatic. - Hyperkalaemia: elevated serum potassium levels. - Cough: mild to moderate respiratory irritation. - Fatigue: generalized tiredness. - Renal impairment: rise in serum creatinine.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure requiring medical intervention. - Hepatic injury: abnormal liver enzymes or jaundice. - Myocardial infarction: rare occurrence of acute coronary syndrome. - Anaphylaxis: life‑threatening allergic reaction. - Acute kidney injury: sudden loss of renal function.

Before initiating Neparvis, clinicians should evaluate patient-specific factors and monitor relevant parameters.

- Blood pressure monitoring: check for hypotension after each dose adjustment. - Renal function: assess serum creatinine and eGFR regularly. - Electrolytes: monitor potassium levels to avoid hyperkalaemia. - History of angioedema: avoid use in patients with prior episodes. - Concomitant ACE inhibitors: ensure a 36‑hour washout period to reduce angioedema risk. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Neparvis interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - ACE inhibitors: concurrent use increases risk of angioedema. - Aliskiren in diabetic patients: may cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics: can precipitate dangerous hyperkalaemia. - NSAIDs: may impair renal function and blunt antihypertensive effect. - Strong CYP3A4 inhibitors: can increase sacubitril exposure.

Moderate Interactions (Monitor Closely): - Loop diuretics: additive blood‑pressure lowering; monitor volume status. - Lithium: risk of lithium toxicity; check serum levels. - Other antihypertensives: may require dose adjustments to avoid excessive hypotension. - Rifampin: may reduce sacubitril/valsartan plasma concentrations. - Antidiabetic agents: monitor glucose control as blood‑pressure changes can affect insulin sensitivity.